Oncotarget

Research Papers:

Association of SOX2 and Nestin DNA amplification and protein expression with clinical features and overall survival in non-small cell lung cancer: A systematic review and meta-analysis

Qingbao Li, Fang Liu, Yuan Zhang, Lei Fu, Cong Wang, Xuan Chen, Shanghui Guan and Xiangjiao Meng _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:34520-34531. https://doi.org/10.18632/oncotarget.9145

Metrics: PDF 928 views  |   HTML 868 views  |   ?  


Abstract

Qingbao Li1, Fang Liu2, Yuan Zhang3, Lei Fu4, Cong Wang5, Xuan Chen5, Shanghui Guan5, Xiangjiao Meng4

1Department of Cardiac Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, 250021, China

2Department of Image, Shandong Medical College, Jinan, 250002, China

3Department of Laboratory Medicine, Shandong Medical College, Jinan, 250002, China

4Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, 250117, China

5Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, 250012, China

Correspondence to:

Xiangjiao Meng, email: sdxjmeng@163.com

Keywords: meta-analysis, SOX2, Nestin, clinical outcome, non-small cell lung cancer

Received: January 04, 2016     Accepted: April 16, 2016     Published: May 02, 2016

ABSTRACT

Up to now, the prognosis of non-small cell lung cancer (NSCLC) is poor. With progress of cancer biology, a number of genes have been investigated for predicting prognosis of NSCLC, such as cancer stem cell markers SRY (sex determining region Y)-box 2 (SOX2) and Nestin. Recently, a series of studies have been performed to examine the associations of SOX2 and Nestin with clinical parameters and prognosis in NSCLC, however, the results were not consistent. In the present study, we conducted a systematic review and meta-analysis to summarize the associations. Four English databases (PubMed, ISI web of science, Embase, and Ovid) were used to search the relevant studies with the last date of November 10, 2015. The pooling analyses were stratified by DNA amplification and protein expression. The pooling ORs or HRs were used to assess the strength of the associations. Finally, we included 19 articles for SOX2 and six articles for Nestin according to the inclusion and exclusion criteria. The pooling analyses revealed that there were significant associations between SOX2 DNA amplification and clinical features of NSCLC, gender, smoking status, squamous cell cancer (SCC) histology, and differentiations. And significant associations were also identified between SOX2 protein expression and clinical parameters, smoking status and SCC histology. For Nestin, its protein expression was correlated with lymph node metastasis and stage. Simultaneously, we found that high/positive SOX2 alterations, either DNA amplification or protein expression, were favorable for overall survival (OS) in NSCLC. On the contrary, high/positive Nestin protein expression was poor for OS.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 9145